Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria I Harrell

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
JAMA Oncology|January 1, 2016
Inherited Mutations in Women With Ovarian CarcinomaBarbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid TumorsAndrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
JAMA Oncology|January 1, 2016
Inherited Mutations in Women With Ovarian CarcinomaBarbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid TumorsAndrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Pageof 4